Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 119

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 119
---
 has agreed to indemnify
the selling shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

| 64 |

We agreed to keep this prospectus
effective until no holder owns any warrants or Depositary Shares issuable upon exercise thereof; provided, however, that we will not be
required to maintain effectiveness so long as the securities may be resold by the selling shareholders without registration and without
regard to any volume or manner-of-sale limitations by reason of Rule 144, and without the requirement for the Company to be in compliance
with the current public information under Rule 144 under the Securities Act or any other rule of similar effect. The resale securities
will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in
certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.

Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market
making activities with respect to the Depositary Shares for the applicable restricted period, as defined in Regulation M, prior to the
commencement of the distribution. In addition, the selling shareholders will be subject to applicable provisions of the Exchange Act and
the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Depositary Shares
by the selling shareholders or any other person. We will make copies of this prospectus available to the selling shareholders and have
informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance
with Rule 172 under the Securities Act).

| 65 |

<div align='center'>EXPENSES OF THE OFFERING</div>

The following table sets
forth the expenses payable by us in connection with the sale and distribution of the securities being registered hereby. All amounts shown,
other than the SEC registration fee, are estimates:

| SEC registration fee    | $ |    904 |
| Printing and engraving  |   |  5,000 |
| Accounting services     |   | 15,000 |
| Legal fees and expenses |   | 50,000 |
| Miscellaneous           |   |  5,000 |
| Total                   | $ | 75,904 |

<div